Celularity Inc. — Filing identity and reporting period
Important discrepancy: The supplied filing is GX Acquisition Corp.’s Form 10-K, not a Celularity Inc. filing. It covers the fiscal year ended December 31, 2019, not standalone fourth-quarter results. GX Acquisition was a blank-check company seeking a business combination; it had not begun operating activities or selected a target by year-end.
Financial results and position
- 2019 results: Net income was $2.513 million, comprising $3.753 million of trust-account interest income, offset by a $7,871 unrealized investment loss, $564,339 of operating and formation costs, and $668,230 of income-tax expense. The filing reports a basic and diluted loss per share of $0.03 after excluding trust earnings attributable to redeemable shares.
- Prior period: From inception on August 24, 2018 through December 31, 2018, the company recorded a $1,098 net loss, entirely from operating costs. The periods are not directly comparable in length or activity.
- Cash flow: Operating activities used $1.098 million in 2019. Investing activities used $286.849 million, primarily reflecting trust funding, net of $651,000 withdrawn for taxes. Financing activities provided $288.839 million. No operating revenue was reported.
- Year-end liquidity and assets: Cash outside the trust was $917,007; trust-account securities were $290.595 million, invested in short-term U.S. Treasury bills. Total assets were $291.605 million. The company stated that $279.782 million was available for a business combination after deferred underwriting fees, before transaction costs and expenses.
- Liabilities and obligations: Total liabilities were $11.042 million, including $10.813 million of deferred underwriting fees and $229,094 of current liabilities. There was no long-term debt. Stockholders’ equity was $5.000 million; $275.564 million of Class A shares was classified as temporary equity because of possible redemption.
- Margins and operating performance: Operating margins are not meaningful because the company had no operating revenue or business operations.
Material changes and financing
GX Acquisition completed its IPO in May 2019, selling 28.75 million units at $10 each for $287.5 million gross proceeds, and issued 7 million private-placement warrants for $7 million. Total transaction costs were $16.473 million, including $10.813 million of deferred underwriting fees. The trust held $290.595 million at year-end; cash outside the trust was $917,007, compared with $24,707 at December 31, 2018. No operating business or revenue stream was added during 2019.
Outlook, risks, and unusual items
- The company had until May 23, 2021 to complete a business combination; otherwise it was required to wind up and redeem public shares, while warrants could expire worthless. Public-share redemption was subject to a minimum $5,000,001 net tangible asset requirement and other transaction conditions.
- Management expected ongoing costs to identify and evaluate targets. It said it did not expect to need additional funds for ordinary operating expenditures, but acknowledged that additional financing might be required to complete a transaction or meet redemption-related cash requirements. Sponsor and affiliate loans were possible but not committed.
- Key risks included failure to find or complete a suitable transaction by the deadline, redemption levels reducing available cash, financing and dilution, competition for targets, conflicts of interest involving the sponsor and management, creditor claims against trust assets, and the possibility that warrants would be unexercisable or worthless.
- The filing discussed COVID-19 as a potential disruption to the search process and prospective targets; it was not identified as an adjusting subsequent event. Management reported no subsequent event requiring adjustment or disclosure in the financial statements.
- Management concluded disclosure controls were effective as of December 31, 2019. The filing did not include management’s assessment or auditor attestation of internal control over financial reporting, citing the transition period for newly public companies.
Investor facts to verify
- Confirm the intended issuer: this document is for GX Acquisition Corp., not Celularity Inc.
- Confirm whether annual 2019 figures, rather than fourth-quarter-only results, are the requested period; the filing does not provide clear standalone Q4 financial results.
- Review the distinction between reported net income of $2.513 million and loss per share of $0.03, including the allocation of trust-account earnings to redeemable shares.
- Verify trust-account funds available after deferred underwriting fees, taxes, redemptions, and any transaction-related conditions.
- Assess sponsor indemnity capacity and potential creditor claims that could reduce public shareholders’ trust distributions.
- Check subsequent filings for developments after the March 23, 2020 filing date, including business-combination progress and effects of COVID-19.